Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKACA | P17612 | 2/20 | 0.70 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.66 |
| ▸ | MARS1 | P56192 | 1/20 | 0.64 |
| ▸ | P2RY1 | P47900 | 4/20 | 0.64 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.64 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.64 |
| ▸ | SRC | P12931 | 2/20 | 0.64 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.64 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.64 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.64 |
| ▸ | LDHA | P00338 | 1/20 | 0.64 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.64 |
| ▸ | FBP1 | P09467 | 1/20 | 0.64 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.64 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.64 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.64 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.64 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6704430 | 0.88 | PRKACA (0.75) | PRKACAPLA2G2AMARS1P2RY1ADORA1 | |
| SCHEMBL9295626 | 0.87 | AHCY (0.71) | PRKACAMARS1P2RY1ADORA1P2RY2 | |
| SCHEMBL9295615 | 0.87 | AHCY (0.71) | PRKACAMARS1P2RY1ADORA1P2RY2 | |
| SCHEMBL7226454 | 0.86 | HINT1 (0.78) | PRKACAPLA2G2AMARS1P2RY1ADORA1 | |
| SCHEMBL3432901 | 0.86 | PRKACA (0.71) | PRKACAPLA2G2AMARS1P2RY1ADORA1 | |
| SCHEMBL1000840 | 0.86 | HINT1 (0.78) | PRKACAPLA2G2AMARS1P2RY1ADORA1 | |
| SCHEMBL2463542 | 0.85 | PRKACA (0.73) | PRKACAMARS1P2RY1ADORA1P2RY2 | |
| SCHEMBL1757017 | 0.85 | ADORA1 (0.73) | PRKACAPLA2G2AMARS1P2RY1ADORA1 | |
| SCHEMBL19859780 | 0.85 | ADORA1 (0.73) | PRKACAPLA2G2AMARS1P2RY1ADORA1 | |
| SCHEMBL9426538 | 0.85 | PRKACA (0.73) | PRKACAMARS1P2RY1ADORA1P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 173 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3387150-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | Novartis AG (CH) | 2018-10-17 | — | — | EP | claimed |
| WO-2017098468-A1 | LABEL-FREE ANALYSIS OF RNA CAPPING EFFICIENCY USING RNASE H, PROBES AND LIQUID CHROMATOGRAPHY/MASS SPECTROMETRY | NOVARTIS AG (CH) | 2017-06-15 | — | — | WO | claimed |
| WO-2026103936-A1 | CHEMICALLY MODIFIED CIRCULAR RNA MOLECULE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 上海元码智药生物技术有限公司 | 2026-05-21 | — | — | WO | disclosed |
| CN-122060818-A | Chemically modified circular RNA molecules, methods of making and uses thereof | 上海元码智药生物技术有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4691484-A2 | INFLUENZA MRNA VACCINES | CureVac SE (DE) | 2026-02-11 | — | — | EP | disclosed |
| US-12508308-B2 | Influenza mRNA vaccines | CureVac SE (DE) | 2025-12-30 | — | — | US | disclosed |
| US-12492236-B2 | Fusion proteins for the treatment of cardiometabolic diseases | SHATTUCK LABS, INC. (US) | 2025-12-09 | — | — | US | disclosed |
| WO-2025125630-A1 | METHOD FOR BIOPROTAC DESIGN | MEDIMMUNE LIMITED (GB) | 2025-06-19 | — | — | WO | disclosed |
| US-20240309346-A1 | COMPOSITIONS COMPRISING A VARIANT CAS12I4 POLYPEPTIDE AND USES THEREOF | Arbor Biotechnologies, Inc. | 2024-09-19 | — | — | US | disclosed |
| US-20240262881-A1 | FUSION PROTEINS FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES | SHATTUCK LABS, INC. | 2024-08-08 | — | — | US | disclosed |
| WO-2024151975-A1 | DETECTING DEGRADATION OF A POLYNUCLEOTIDE BY RAMAN SPECTROSCOPY | LEDNEV IGOR (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20140242154-A1 | Compounds, Compositions, Methods, and Kits Relating to Telomere Extension | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242155-A1 | Compounds, Compositions, Methods, and Kits Relating to Telomere Extension | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| WO-2014093924-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-1200097-B1 | METHOD FOR CONTROLLING THE FIDELITY AND THE PROCESSIVITY OF REVERSE TRANSCRIPTASE BY INCORPORATING AND POLYMERISING NUCLEOTIDE ANALOGUES ACCEPTED AS SUBSTRATES OF THE REVERSE TRANSCRIPTION RESPONSE WITHOUT BLOCKING ITS ELONGATION | VIGILENT TECHNOLOGIES (FR) | 2014-01-08 | — | — | EP | disclosed |
| WO-2011071931-A2 | RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS | KARIKO KATALIN (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20110143397-A1 | RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-06-16 | — | — | US | disclosed |
| EP-1979364-A2 | RNA CONTAINING MODIFIED NUCLEOSIDES AND METHODS OF USE THEREOF | The Trustees of The University of Pennsylvania (US) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007024708-A2 | RNA CONTAINING MODIFIED NUCLEOSIDES AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2007-03-01 | — | — | WO | disclosed |
| US-6727059-B1 | ADMINISTERING A NUCLEOSIDE ANALOG THAT HAS A 3' HYDROXYL GROUP LOCATED ON THE C3' CARBON OF THE 2'-DEOXYRIBOSE, FOR EXAMPLE DUTP; FOR RETROID VIRUS INFECTIONS SUCH AS HIV; MIXTURE WITH REVERSE TRANSCRIPTASE INHIBITORS SUCH AS AZT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2004-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508308-B2 | Influenza mRNA vaccines | RNMT, RNGTT, AMPD3 | PRKACA 1983/4885PLA2G2A 589/4885MARS1 1593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.